Clinical observation of intraoperative local chemotherapy with lobaplatin in breast cancer modified radical mastectomy

Background: To evaluate the clinical efficacy of intraoperative local chemotherapy with Lobaplatin in patients underwent breast cancer modified radical mastectomy. Patients and methods: 50 cases of primary breast cancer patients intended to receive modified radical mastectomy were included and randomly divided into two groups. In observation group, operative wound was washed and steeped by physiological saline containing 50 mg Lobaplatin for 15 min. After sucking out the washing fluid, another 50 mg Lobaplatin was multi-point sprayed in tumor bed, axillary lymph node dissection area, and any other potential area of residual cancer cells before flap suture. Control group only received a treatment of same amount of physiological saline. Then, drug safety, short-term effects and long-term results were tracked and compared. Results: Several postoperative adverse effects including myelosuppression (number of leukocytes and platelets), hepatic and renal functions (serum creatinine and alanine aminotransferase), local pain as well as gastrointestinal reactions (nausea and vomiting) and primary healing time showed no significant difference between two groups (P > 0.05). Positive rate of exfoliative tumor cytology in observation group was remarkably lower than control group (X-2=5.1, P < 0.05). The 3-year overall survival rates seemed no different between two groups (88.9% vs. 87.5%, P > 0.05), whereas the 3-year disease free survival in observation group was higher than that in control group (90.0% vs. 79.1%, P < 0.05). Conclusion: Intraoperative Lobaplatin chemotherapy in patients undergoing breast cancer modified radical mastectomy is safe and effective and could improve 3-year disease free survival. It is worthy of further clinical promotion.